Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth

Natalia Gonzalez Caldito*, Edith L. Graham, Elena Grebenciucova

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Late-onset neutropenia (LON) is a rare adverse event that has not been reported from in utero exposure. We describe a case of LON in an infant, whose mother had neuromyelitis optica and received rituximab in the third trimester due to re-emergence of CD19 B cells. The newborn was born without complications but 2 months later was found to have grade IV neutropenia. No etiology was identified. Neutropenia self-resolved within 1 week. This case emphasizes an unmet need for developing guidelines and protocols to manage in utero rituximab exposure.

Original languageEnglish (US)
Pages (from-to)272-274
Number of pages3
JournalMultiple Sclerosis Journal
Volume30
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • CD20 monoclonal antibody
  • Rituximab
  • delayed-onset neutropenia
  • neuromyelitis optica spectrum disorder
  • pregnancy
  • side effects

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth'. Together they form a unique fingerprint.

Cite this